share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  08/21 13:22
Moomoo AI 已提取核心訊息
On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.
On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.
2024年8月20日,SeaStar醫療控股有限公司與H.C. Wainwright & Co., LLC達成了一項市場發售協議,通過「市場發售」計劃出售其普通股的股份。銷售將在納斯達克證券交易市場或公司股票的其他交易市場上進行。SeaStar醫療將向Wainwright支付總銷售額3.0%的佣金,並提供賠償和費用報銷。協議包括慣常的陳述、保證和條件,並且公司有權中止要約或不出售任何股份。這一發售將持續進行,直到任何一方終止協議。這些股份將根據公司的存貨註冊聲明和相關的招股說明書發行。一份涵蓋了價值2500萬美元股份銷售的招股補充說明書於同一天向美國證券交易委員會提交。這項ATm協議在向美國證券交易委員會提交的最新報告的附件10.1中有詳細說明,關於股份發行的法律意見將包含在附件5.1中,由Dorsey & Whitney律師事務所提供。
2024年8月20日,SeaStar醫療控股有限公司與H.C. Wainwright & Co., LLC達成了一項市場發售協議,通過「市場發售」計劃出售其普通股的股份。銷售將在納斯達克證券交易市場或公司股票的其他交易市場上進行。SeaStar醫療將向Wainwright支付總銷售額3.0%的佣金,並提供賠償和費用報銷。協議包括慣常的陳述、保證和條件,並且公司有權中止要約或不出售任何股份。這一發售將持續進行,直到任何一方終止協議。這些股份將根據公司的存貨註冊聲明和相關的招股說明書發行。一份涵蓋了價值2500萬美元股份銷售的招股補充說明書於同一天向美國證券交易委員會提交。這項ATm協議在向美國證券交易委員會提交的最新報告的附件10.1中有詳細說明,關於股份發行的法律意見將包含在附件5.1中,由Dorsey & Whitney律師事務所提供。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息